NCT00485719View on ClinicalTrials.gov

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Cancer
Interventions
DRUG

XL765 (SAR245409)

Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally

Trial Locations (4)

48201

Investigational Site Number 1302, Detroit

68198

Investigational Site Number 1435, Omaha

78229

Investigational Site Number 1402, San Antonio

08035

Investigational Site Number 3411, Barcelona

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY